Hernandez-Martín A, Aranegui B, Escámez M J, de Lucas R, Vicente A, Rodríguez-Díaz E, Bernabeu-Wittel J, Gonzalez-Hermosa R, García-Patos V, Ginarte M, Mascaró J M, Corredera C, Baselga E, Santiago J L, Chaves A, Román C, Evole M, Martin-Santiago A, Torrelo A, Del Río M, Feito M, Gonzalez-Enseñat M A, Romero G, Morcillo-Makow E, Abaitua I, García-Doval I
Department of Dermatology, Hospital Infantil del Niño Jesús, Madrid, Spain.
Actas Dermosifiliogr. 2013 Dec;104(10):890-6. doi: 10.1016/j.ad.2013.03.006. Epub 2013 Jun 27.
Dystrophic epidermolysis bullosa (DEB) is a rare disease that represents a heavy burden for both the patient and the health care system. There are currently no data on the prevalence of DEB in Spain.
To determine the prevalence of DEB in Spain.
We used data from 3 incomplete population-based sources (hospital dermatology departments, diagnostic laboratories performing antigenic mapping, genetic testing or both, and the Spanish Association of Epidermolysis Bullosa Patients [DEBRA]) and combined them using the 3-source capture-recapture methodology.
We identified 152 living DEB patients. The estimated prevalence of DEB was 6.0 cases per million (95% CI, 4.2-11.8) in adults and 15.3 (95% CI, 10.4-40.8) in children under 18 years of age. The data indicated that 77% of the patients were not being followed up in specialized centers of reference; 65% had not had a genetic diagnosis, and 76% were not members of DEBRA.
The prevalence of DEB in Spain is 6.0 patients per million (95% CI, 4.2-11.8), a figure higher than previous estimates in many areas, but similar to those found in other southern Europe countries. The north-south difference may represent real geographic differences in prevalence, but it might be due to the fact that most of the data come from registries with a lower than expected catchment. Many patients are not being followed up in centers of reference, do not have genetic diagnosis, and are not members of patients' associations, suggesting that there is room for considerable improvement in their care.
营养不良性大疱性表皮松解症(DEB)是一种罕见疾病,给患者和医疗保健系统都带来了沉重负担。目前西班牙尚无关于DEB患病率的数据。
确定西班牙DEB的患病率。
我们使用了3个不完整的基于人群的数据源(医院皮肤科、进行抗原图谱分析、基因检测或两者皆有的诊断实验室,以及西班牙大疱性表皮松解症患者协会[DEBRA])的数据,并采用三源捕获-再捕获方法将它们合并。
我们识别出152名存活的DEB患者。DEB的估计患病率在成年人中为每百万6.0例(95%置信区间,4.2 - 11.8),在18岁以下儿童中为15.3例(95%置信区间,10.4 - 40.8)。数据表明,77%的患者未在专门的参考中心接受随访;65%未进行基因诊断,76%不是DEBRA的成员。
西班牙DEB的患病率为每百万6.0例(95%置信区间,4.2 - 11.8),这一数字高于许多地区先前的估计,但与其他南欧国家的患病率相似。南北差异可能代表患病率的真实地理差异,但也可能是由于大多数数据来自覆盖范围低于预期的登记处。许多患者未在参考中心接受随访,未进行基因诊断,也不是患者协会的成员,这表明在他们的治疗方面仍有很大的改进空间。